Le Lézard
Classified in: Health, Science and technology
Subject: PDT

Paragon Genomics Launches ParagonDesignertm Online Tool That Makes It Easy To Design Custom CleanPlex® NGS Assays


HAYWARD, Calif., Sept. 20, 2018 /PRNewswire/ -- Paragon Genomics, Inc. today announced the launch of ParagonDesignertm, its web-based tool that enables rapid design of CleanPlex® Custom NGS Panels. The online portal features a streamlined, user-friendly interface that simplifies the assay design process, making it easy for researchers to build customized next-generation sequencing (NGS) assays addressing their specific needs. The custom panels are powered by Paragon Genomics' unique CleanPlex technology, an ultra-high multiplexed PCR-based target enrichment chemistry that makes it possible to include a large number of genomic targets in a single assay.

"ParagonDesigner allows our customers to build CleanPlex Custom NGS assays with just a few clicks of the mouse," said Tao Chen, founder and CEO of Paragon Genomics. "By combining our proprietary target enrichment chemistry and our advanced design algorithm in an assessible online tool, we make it easy for researchers and assay developers to design high quality NGS panels optimized to meet their needs. We provide the best hands-on expert support in the industry to all our customers, and we are proud of our rapid turnaround time?just two to four weeks."

Paragon Genomics design experts are available to provide hands-on personalized support to all ParagonDesigner customers, even for small orders. The company delivers custom NGS panels in 2 to 4 weeks. Other providers typically take six weeks or longer.

With ParagonDesigner, users define the content of their custom NGS assays by submitting their targets online. ParagonDesigner features a database of more than 1,300 pre-designed, clinically-relevant human genes, allowing CleanPlex Custom NGS Panels to be instantly assembled for most applications. The design tool also issues a report on the estimated panel size and design coverage for review prior to submission.

Paragon Genomics' CleanPlex technology is a proprietary, ultra-high multiplexed PCR-based target enrichment technology for NGS featuring an innovative PCR background cleaning chemistry that allows tens of thousands of amplicons to be multiplexed in a single pool of reaction, allowing a large number of targets to be interrogated in a single assay. The CleanPlex technology is combined with Paragon Genomics' advanced panel design algorithm to create optimized custom NGS assays tailored to the user's application and input type, ensuring high sequencing performance and assays that work the first time without further optimization. Users have designed CleanPlex Custom NGS Panels for a wide variety of applications, including tumor profiling, early cancer detection, high-throughput genotyping and gene expression analysis. CleanPlex Custom NGS Panels can be designed for sequencing on either Illumina or Ion Torrent platforms.

For more information about ParagonDesigner and CleanPlex Custom NGS Panels, visit www.paragongenomics.com/custom_panels.

Paragon Genomics' CleanPlex® products are for Research Use Only.

About Paragon Genomics
Paragon Genomics (paragongenomics.com) is a leader in amplicon-based target enrichment and library preparation solutions to accelerate the development of next-generation sequencing (NGS)-based assays for research and clinical testing. The company designs high performance and ultra-multiplexed amplicon NGS panels and develops NGS library preparation chemistries for analyzing difficult, clinically-relevant samples. It strives to make the design of custom NGS assays easily available to a broad range of users, with expert counsel and rapid turnaround. Privately-held Paragon Genomics is located in Hayward, California. 

Contacts:                                

Media:

Paragon Genomics, Inc.     

BLL Partners, LLC

Edward Jan                          

Barbara Lindheim

Head of Product Marketing 

[email protected] 

[email protected]

(917) 355-9234

 

SOURCE Paragon Genomics


These press releases may also interest you

at 16:20
The Board of Directors of Revvity , today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 9, 2024 to all shareholders of record at the close of business on July 19, 2024. About Revvity ...

at 16:20
Edwards Lifesciences today reported financial results for the quarter ended March 31, 2024. Highlights and Outlook Q1 sales grew 10% on a reported and constant currency1 basis to $1.6 billion Q1 TAVR sales grew 6%; constant currency sales...

at 16:20
Juniper Networks , a leader in secure, AI-Native Networks, today reported preliminary financial results for the three months ended March 31, 2024. Proposed Merger with Hewlett Packard Enterprise As announced on January 9, 2024, Hewlett Packard...

at 16:20
FICO , a leading predictive analytics and decision management software company, today announced results for its second fiscal quarter ended March 31, 2024. Second Quarter Fiscal 2024 GAAP Results Net income for the quarter totaled $129.8 million,...

at 16:17
The board of directors of Texas Instruments Incorporated today declared a quarterly cash dividend of $1.30 per share of common stock, payable May 21, 2024, to stockholders of record on May 8, 2024.     About Texas Instruments Texas Instruments...

at 16:15
Snap Inc. today announced financial results for the quarter ended March 31, 2024. "The value we provide our community and advertising partners has translated into improved financial performance," said Evan Spiegel, CEO. "Our large, growing, and...



News published on and distributed by: